ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
D0816C00025: A Phase 1, Open-label, Parallel Group Study to Investigate Olaparib Safety andTolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours
Protocol ID
D0816C00025
Disease (Sub Disease)
Solid Tumours
Diagnosis Stage
Relapsed/refractory
Location
NSW, WA
Sponsor
AstraZeneca
Links
External Registry ≫
Trial Status
Open
Sites
Perth Children's Hospital
Sydney Children's Hospital
Study Type
Treatment
Phase
Phase 1
Age Eligibility
0 Years to 18 Years
International registry ID's
NCT04236414
Back to Registry
Study Title D0816C00025: A Phase 1 Open-label Parallel Group Study to Investigate Olaparib Safety andTolerability Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours
Protocol ID D0816C00025
Disease (Sub Disease) Solid Tumours
Diagnosis Stage Relapsed/refractory
Location NSW / WA
Sponsor AstraZeneca
Links https://clinicaltrials.gov/ct2/show/NCT04236414
Trial Status Open
Trial Open Date 01/11/2022
Sites Perth Children's Hospital / Sydney Children's Hospital
Study Type Treatment
Phase Phase 1
Age Eligibility 0 Years to 18 Years
International registry ID's NCT04236414

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.